icone plus 
	     
	    
	    
	    	
	
	
		
		
	
	     
	    
		
			
		 
		
			
		 
		
			
			
			
		 
		
			
				Contact Abonnez-vous aux actualités 
			 
		 
		
	 
 
     
    
   
  
  
	 
	 
	 
	 
	 
 
  
	 
	
		
			
			
			
				
  
    
  
	
    
        
            
            
                
                
	                
	                    
	                 
                    
                    
                        
                            
                            
                                
 
 
  
   Autorisation d’accès précoce refusée  à la spécialité DUPIXENT (dupilumab).  
    
   
 
                            
							
     
                     
                 
                
    
	See also 
		
		
            
                  
                  		Décision d'accès précoce
				  
                  14/11/2024
                  
                  
             
			
		 
     
                
                
             
         
     
	
 
        
  
			
		
	 
	
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
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
309CVnqyExWpEX36